GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

Phase 1

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: GSK1070806
Drug: Placebo

First Posted Date: 2022-10-21

Last Posted Date: 2024-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 38

Registration Number: NCT05590338

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Biological: RSVPreF3 OA investigational vaccine

First Posted Date: 2022-10-21

Last Posted Date: 2025-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1544

Registration Number: NCT05590403

Locations: 🇪🇸
GSK Investigational Site, Vigo, Spain

Managed Access Program for Momelotinib in Myelofibrosis

Conditions: Myelofibrosis
Primary Myelofibrosis

First Posted Date: 2022-10-17

Last Posted Date: 2023-11-08

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT05582083

Phase 2b Study of GSK4532990 in Adults With NASH

Phase 2

Active, not recruiting

Conditions: Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Placebo
Drug: GSK4532990

First Posted Date: 2022-10-17

Last Posted Date: 2025-05-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 284

Registration Number: NCT05583344

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA vaccine
Biological: FLU vaccine

First Posted Date: 2022-10-06

Last Posted Date: 2024-03-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1045

Registration Number: NCT05568797

Locations: 🇬🇧
GSK Investigational Site, Peterborough, United Kingdom

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Dostarlimab
Drug: Pembrolizumab
Drug: Belrestotug
Drug: Nelistotug

First Posted Date: 2022-10-04

Last Posted Date: 2024-11-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 340

Registration Number: NCT05565378

Locations: 🇬🇧
GSK Investigational Site, Wolverhampton, United Kingdom

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Combination Product: GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
Biological: GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system
Biological: GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
Biological: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1
Biological: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2